Enfin disponible en France, grâce à une étonnante formule France, 100% naturelle, vous pouvez maintenant dire stop à vos problèmes d’impuissance et à vos troubles de la virilité. Cette formule révolutionnaire agit comme un véritable achat cialis
naturel. Ses résultats sont immédiats, sans aucun effet secondaire et vos érections sont durables, quelque soit votre âge. Même si vous avez plus de 50 ans !
December 8, 2009
To: Kern County Health Care Providers RE: Novel Influenza A H1N1 Antiviral Treatment
If pandemic 2009 (H1N1) disease is suspected, it is strongly recommended that antiviral
treatment should not be delayed by influenza diagnostic testing
Although antiviral treatment is most effective when initiated within 48 hours of influenza illness onset,
studies have shown that hospitalized patients still benefit when treatment with oseltamivir is started
more than 48 hours after illness onset. Outpatients, particularly those with risk factors for severe
illness who are not improving, might also benefit from antiviral treatment initiated more than 48 hours
after illness onset.
All hospitalized patients with suspected or confirmed 2009 H1N1 should receive antiviral treatment
with a neuraminidase inhibitor – either oseltamivir or zanamivir – as early as possible after illness
onset. Moderately ill patients and those who appear to be getting worse can also benefit from
treatment with neuraminidase inhibitors. Those at risk for severe illness include:
• Children younger than 5,
especially children younger than 2 years old • • • People who have chronic medical conditions including:
Neurological and neurodevelopment conditions [including disorders of the brain, spinal
cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy (seizure disorders), stroke, intellectual disability (mental retardation), moderate to severe developmental delay, muscular dystrophy, or spinal cord injury].
Chronic lung disease (such as chronic obstructive pulmonary disease [COPD] and
(such as congenital heart disease, congestive heart failure and coronary
Blood disorders (such as sickle cell disease) Endocrine disorders (such asmellitus) Kidney disorders Liver disorders Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders) Weakened immune system due to disease or medication (such as people with HIV or
People younger than 19 years of age who are receiving long-term aspirin therapy
Groups at higher risk of developing severe disease include children younger than two years old and pregnant women with preexisting medical conditions. Pregnant women are at increased risk for complications, such as; spontaneous abortion, preterm birth, and fetal distress. Also included are
people with lung diseases, metabolic disorders, weakened immune systems and certain neurological
conditions. H1N1 also poses greater risk of complications in obese individuals and disadvantaged
populations. These patients with suspected or confirmed 2009 H1N1 infection need closer
observation and antiviral treatment as early as possible.
Although antiviral medications are recommended for treatment of 2009 H1N1 in patients with risk
factors for severe disease, some people without risk factors may also benefit from antivirals. Not yet
recorded in Kern County, the CDC reports to date that roughly 40% of children and 20% of adults
hospitalized with complications of 2009 H1N1 did not have risk factors.
Risk factors in previously
healthy persons that predict increased risk of progressive disease or severe complications are not
The bulk of admissions and fatalities for respiratory complications from seasonal flu are people over
the age of 65. Due to most people today having little or no immunity to 2009 (H1N1), studies are
suggesting that the pandemic is severely affecting a wider range of ages than has been previously
seen with influenza. Symptoms can range from a mild headache and sore throat with or without
fever to rapidly progressive, life-threatening pneumonia. Even though the majority of people infected
with 2009 H1N1 will develop mild to moderate disease, the virus is still capable of causing life
threatening complications in children and young to middle-aged adults.
The 2009 H1N1 virus is capable of infecting the lower respiratory tract, heightening the risk of lung
disease and respiratory failure. According to reports, diagnosing H1N1 may be more difficult in
patients with lower respiratory illness because initial laboratory tests sometimes fail to pick up the
infection in specimens from the nose and throat. Samples from the trachea and bronchi may provide
a more accurate test result.
Commercially available diagnostic tests that produce a rapid result may not detect many infections.
These tests should not be the only diagnostic method used to determine treatment or discontinue
infection control measures. The earlier antiviral treatment is administered, the greater the
effectiveness for the patient. Although pediatric oseltamivir suspension is in short supply, there are
also oseltamivir capsules that can be compounded and mixed with syrup at home.
For more information, please visit the Doctor’s Corner on the Kern County Department of Public
Health website at
Should you have any additional questions, comments, or concerns please feel free to contact the Kern County Department of Public Health, Communicable Disease Control at (661) 868-0420.
Case 1-2013: Filarial Lymphoedema of Upper and Lower limbs Talaat Fathy, Ashraf Metwally, Amal A Gouda, Mona Abdelmaksoud Tropical Medicine Department, Zagazig University Hospitals Case records of Endemic and Tropical Medicine Department, Zagazig University Case presentation: Differential diagnosis of lymphoedema: Twenty two-year-old house wife from Sharkeya, Egypt presented
It’s Changing Faster than Moore’s Law, but Is U.S. Policy Keeping Pace?In 1990, the U.S. launched an audacious scientific endeavor with the potential to changethe practice of medicine when the National Institutes of Health and the Department ofEnergy joined with the international community in a quest to sequence all 3 billion let-ters, or base pairs, in the human genome, which is the complete